Asenapine Maleate
₹2,000.00
Applications
This medication is used to treat certain mental/mood disorders (such as schizophrenia, bipolar disorder). Asenapine helps you to think more clearly, feel less nervous, and take part in everyday life. It may also help to decrease hallucinations (hearing/seeing things that are not there) and prevent severe mood swings.
Description
Asenapine is used to treat schizophrenia in adults. It is also used alone or together with lithium or valproate to treat symptoms of psychotic (mental) disorders, such as mania or bipolar disorder. This medicine should not be used to treat behavioral problems in older adult patients who have dementia.
Preparation
Asenapine Maleate is poorly soluble in water. In present work different formulations prepared by using different stabilizers such as Polyvinyal Pyrrolidine K-30, Tween 80 and Poloxamer 188. The Nanoprecpitation technique is simple, less sophisticated technique.
Chemical Properties
Asenapine maleate is a white to off-white crystalline powder with a faint characteristic odor, recognized for its antipsychotic properties and primarily used in the treatment of schizophrenia and bipolar disorder.
Definition
Name Asenapine maleate Drug Entry Asenapine. Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder.
Description
| Product Name | Asenapine Maleate |
| Prescription/Non prescription | Prescription |
| Country of Origin | Made in India |
| Usage | Pharma |
| Molecular Weight | 401.8 g/mol |
| Formula | C21H20ClNO5 |
| Form | Powder |
| Type Of API | Innovative |
| Color | White |
| Grade Standard | Medicine Grade |
| Packaging Size | As Per Requirement |
Our Export Location as a Asenapine Maleate Manufacturer, Supplier, Exporter, Stockist from India.
 Afghanistan
|
 Bosnia and Herzegovina
|
 Cote d’Ivoire
|
 Schaumburg-Lippe*
|
 India
|
Albania
Algeria
Andorra
Angola
Antigua and Barbuda
Argentina
Armenia
Australia
Austria
Austrian Empire
Azerbaijan
Baden
Bahamas
Bahrain
Bangladesh
Barbados
Bavaria
Belarus
Belgium
Belize
Benin (Dahomey)
Bolivia
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mecklenburg-Schwerin
Mecklenburg-Strelitz
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Botswana
Brazil
Brunei
Brunswick and Lüneburg
Bulgaria
Burkina Faso 
Burma
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands
Central African Republic
Central American Federation
Chad
Chile
China
Colombia
Comoros
Congo Free State
Costa Rica
Morocco
Mozambique
Namibia
Nassau
Nauru
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
North German Confederation
North German Union
North Macedonia
Norway
Oldenburg
Oman
Orange Free State
Pakistan
Palau
Panama
Papal States
Croatia
Cuba
Cyprus
Czechia
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Duchy of Parma
East Germany
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Federal Government of Germany
Fiji
Papua New Guinea
Paraguay
Peru
Philippines
Piedmont-Sardinia
Poland
Portugal
Qatar
Republic of Genoa*
Republic of Korea (South Korea)
Republic of the Congo
Romania
Russia
Rwanda
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Grand Duchy of Tuscany
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Hanover
Hanseatic Republics
Hawaii
Hesse
Holy See
Honduras
Hungary
Iceland
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Texas
Thailand
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kingdom of Serbia/Yugoslavia
Kiribati
Korea
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Lew Chew (Loochoo)
Timor-Leste
Togo
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Two Sicilies*
Uganda
Ukraine
Union of Soviet Socialist Republics*
United Arab Emirates
United Kingdom
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Württemberg*
Yemen
Zambia
ZimbabweRelated products
-
- Sale!
- API and intermediate
Etoricoxib
- ₹10,000.00
-
- Sale!
- API and intermediate
Bisacodyl
- ₹5,800.00
Reviews
There are no reviews yet.